Robert L Curtis

US Patent:

20100130965, May 27, 2010

Filed:

Sep 14, 2009

Appl. No.:

12/559377

Inventors:

Robert M. Curtis - Santa Fe NM, US
Randy R. Sibbitt - Helena MT, US

Assignee:

Abbott Vascular Inc. - Santa Clara CA

International Classification:

A61B 18/20
A61B 17/10
A61B 17/08
A61B 18/00
A61B 18/04

US Classification:

606 2, 606139, 606151, 606 32, 606 27

Abstract:

A tissue closure device including a tissue eversion apparatus, and a first and a second, redundant closure element that are placed on the external surface of a tissue puncture wound to enhance the efficacy of closure. The first closure element and the second closure element closure are left resident on the external surface of or in proximity to the tissue puncture wound in order to provide redundancy of closure.

US Patent:

20120089211, Apr 12, 2012

Filed:

Apr 8, 2011

Appl. No.:

13/083029

Inventors:

Robert M. Curtis - Santa Fe NM, US
Phillip Olsen - Cupertino CA, US

Assignee:

Myoscience, Inc. - Redwood City CA

International Classification:

A61F 7/12

US Classification:

607105, 607113

Abstract:

A method for cryogenically treating tissue comprises piercing the skin, inserting a sheath into tissue, and passing a cryoprobe through the sheath into the tissue. The cryoprobe cools a first region of the tissue, is repositioned in the sheath, and then cools a second region of the tissue.

US Patent:

20220347183, Nov 3, 2022

Filed:

Jun 29, 2022

Appl. No.:

17/853005

Inventors:

- Albuquerque NM, US
Alain Romero - Brisbane CA, US
Hugh Smyth - West Lake Hills TX, US
Robert Curtis - Santa Fe NM, US
Adaani Frost - Houston TX, US
Zhen Xu - Rockville MD, US
Revati Shreeniwas - Palo Alto CA, US
Martin Donovan - Austin TX, US

Assignee:

Respira Therapeutics, Inc. - Albuquerque NM

International Classification:

A61K 31/53
A61P 9/12
A61K 9/00
A61K 9/16
A61K 31/192
A61K 31/506

Abstract:

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

US Patent:

20210205318, Jul 8, 2021

Filed:

Jan 11, 2021

Appl. No.:

17/146173

Inventors:

- Albuquerque MN, US
Alain ROMERO - Brisbane CA, US
Hugh SMYTH - West Lake Hills TX, US
Robert CURTIS - Santa Fe NM, US
Adaani FROST - Houston TX, US
Zhen XU - Rockville MD, US
Revati SHREENIWAS - Palo Alto CA, US
Martin DONOVAN - Austin TX, US

International Classification:

A61K 31/53
A61P 9/12
A61K 9/00
A61K 9/16
A61K 31/192
A61K 31/506

Abstract:

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

US Patent:

20200093830, Mar 26, 2020

Filed:

Dec 14, 2017

Appl. No.:

16/469524

Inventors:

- Albuquerque NM, US
Alain ROMERO - Brisbane CA, US
Hugh SMYTH - West Lake Hills TX, US
Robert CURTIS - Santa Fe NM, US
Adaani FROST - Houston TX, US
Zhen XU - Rockville MD, US
Revati SHREENIWAS - Palo Alto CA, US
Martin DONOVAN - Austin TX, US

International Classification:

A61K 31/53
A61K 9/00
A61K 31/192
A61K 31/506
A61K 9/16
A61P 9/12

Abstract:

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

US Patent:

20180369513, Dec 27, 2018

Filed:

Apr 17, 2018

Appl. No.:

15/955508

Inventors:

- Albuquerque NM, US
Dan Deaton - Apex NC, US
Shirley Lyons - Redwood City CA, US
Jeffry Weers - Half Moon Bay CA, US
Robert Curtis - Santa Fe NM, US

International Classification:

A61M 15/00

Abstract:

A unit dose dry powder inhaler includes a base defining a capsule seat that holds a capsule of medicament and an air intake that is in fluid communication with the capsule seat. The intake draws air into the capsule seat to generate rapid capsule precession and centrifugal forces that fluidize and disperse powder agglomerates. Entrained powder is drawn through a grid to disperse powder agglomerates via impaction forces. An inlet funnel between the grid and a dispersion chamber tapers to a small inlet orifice into the dispersion chamber to disperse powder agglomerates via shear forces generated at the orifice. The chamber entrains powder from the inlet funnel and holds an actuator that oscillates during inhalation to disperse powder agglomerates by dynamic impaction with the actuator and increased turbulence within the chamber. A tapered outlet funnel reduces particle velocity and turbulence and provides an exit for air and aerosolized medicament.

US Patent:

20160317542, Nov 3, 2016

Filed:

Dec 9, 2014

Appl. No.:

15/102957

Inventors:

- Albuquerque NM, US
Hugh Smyth - West Lake Hills TX, US
Aileen Gibbons - New York NY, US
Revati Shreeniwas - Palo Alto CA, US
Pravin Soni - Sunnyvale CA, US
Dan Deaton - Apex NC, US
James Hannon - Albuquerque NM, US
Stephen Lermer - Austin TX, US
Robert Curtis - Santa Fe NM, US

Assignee:

Respira Therapeutics, Inc. - Albuquerque NM

International Classification:

A61K 31/53
A61K 47/26
A61M 15/00
A61K 9/00

Abstract:

Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

US Patent:

20150066055, Mar 5, 2015

Filed:

Nov 4, 2014

Appl. No.:

14/532537

Inventors:

- Santa Clara CA, US
Robert M. Curtis - Santa Fe NM, US
Randy R. Sibbitt - Helena MT, US

International Classification:

A61B 17/10
A61B 17/08

US Classification:

606139

Abstract:

A tissue closure device including a tissue eversion apparatus, and a first and a second, redundant closure element that are placed on the external surface of a tissue puncture wound to enhance the efficacy of closure. The first closure element and the second closure element are left resident on the external surface of or in proximity to the tissue puncture wound in order to provide redundancy of closure.